Rising Demand for Non-Invasive Mental Health Treatments: Neuronetics’ TMS Leadership in a $2B+ Market

The mental health crisis is reaching a crescendo. With one in six people worldwide experiencing a mental disorder, the search for effective, non-stigmatizing treatments has never been more urgent. Enter transcranial magnetic stimulation (TMS), a breakthrough therapy now at the forefront of a paradigm shift in mental healthcare. On May 14, 2025—the inaugural National TMS Therapy Awareness Day—Neuronetics, Inc. launched a strategic campaign to destigmatize depression treatment and accelerate adoption of its NeuroStar Advanced Therapy system. This marks a pivotal moment for a market poised to exceed $2 billion by 2029, driven by rising awareness, aging populations, and clinical validation.

The TMS Revolution: Precision, Accessibility, and Hope

NeuroStar, Neuronetics’ flagship product, delivers targeted magnetic pulses to stimulate brain regions affected by depression, anxiety, and OCD—without the side effects of antidepressants. Its FDA clearance for adolescents (15–21 years) in 2024 alone opens a critical demographic, addressing a population often underserved by traditional therapies. With over 7.4 million treatments administered and the largest clinical dataset in the field, NeuroStar’s efficacy is backed by robust evidence. Patient stories, like that of Kristen Gingrich—a social worker who overcame years of treatment-resistant depression—highlight its life-changing potential.

The timing of the Awareness Day, during Mental Health Awareness Month, is no accident. It capitalizes on a cultural moment where destigmatizing mental health care is a societal priority. By spotlighting TMS as a viable alternative to pills, Neuronetics is redefining how depression is treated.

Market Catalysts: Growth Drivers Igniting a $2B+ Opportunity

The TMS market’s trajectory is clear: from $1.4 billion in 2025, it is projected to grow at a 9.9% CAGR to reach $2.04 billion by 2029 (). Three forces are accelerating this ascent:

1. Expanding Insurance Coverage: NeuroStar’s inclusion in Medicare, Tricare, and plans covering 300+ million Americans ensures broad access. As more insurers recognize TMS’s cost-effectiveness—reducing long-term healthcare costs from chronic depression—coverage will broaden further.
2. Aging Populations: The global elderly population is set to double by 2050, with age-related conditions like Alzheimer’s and depression driving demand for non-invasive therapies.
3. Clinical Validation: NeuroStar’s presentation at the 2025 American Psychiatric Association meeting underscores its growing clinical credibility. With peer-reviewed studies demonstrating symptom improvement and protocol optimization, TMS is transitioning from niche to mainstream.

Why Neuronetics is the Leading Play

Neuronetics is not just a participant in this boom—it is the architect. Its dominance is cemented by:
- Technological Superiority: NeuroStar’s Contact Sensing feature ensures precise, consistent treatment delivery, a critical factor in efficacy.
- Market Penetration: Its subsidiary Greenbrook TMS has treated 55,000 patients with over 1.8 million sessions, creating a scalable infrastructure.
- Strategic Partnerships: Collaborations to expand TMS into underpenetrated regions like Asia-Pacific, where mental health awareness is rising rapidly, offer untapped growth avenues.

Critically, the market remains underpenetrated. Today, TMS accounts for less than 5% of depression treatments in the U.S.—a gap Neuronetics is poised to fill.

The Investment Case: A Rare Confluence of Catalysts

For investors, Neuronetics represents a rare opportunity: a high-growth, clinically validated leader in a sector with structural tailwinds. The stock—though not yet publicly traded—could see explosive upside once listed, given its:
- Undervalued Potential: Analysts estimate the company’s enterprise value at $1.5 billion, far below its $2+ billion addressable market.
- Scalability: Its modular systems and training programs allow rapid expansion into new geographies.
- Moat: Patents and clinical data create barriers against competitors, even as the market expands.

Conclusion: Act Now—The Tipping Point is Here

The launch of TMS Therapy Awareness Day signals a turning point. Neuronetics is not just riding a wave—it is creating it. With a market growing at nearly 10% annually, a product proven to save lives, and a strategy to dominate underpenetrated regions, this is a once-in-a-decade investment. The question is no longer whether TMS will disrupt mental healthcare—it is. The only question is: will you be on the right side of this revolution?

Invest now, before the crowd catches on.